ABSTRACT
BACKGROUND: A vast literature exists on doctorally-prepared RNs in academia, but little is known about those in practice settings. PURPOSE: The purpose of this study was to explore demographic, educational, and employment characteristics, as well as practice patterns and professional accomplishments of doctorally-prepared RNs in one practice setting. METHODS: Survey of approximately 100 doctorally-prepared RNs in an integrated health system were surveyed. DISCUSSION: Doctors of Nursing Practice (DNPs) outnumber PhDs three to one in the institution. Several statistically significant differences exist between them: DNPs are younger and most likely hold advanced practice nursing positions; PhDs are 10 years older and more likely hold administrative or leadership positions. Little evidence exists that neither nurses nor administrators understand the skills and knowledge that doctorally-prepared RNs bring to the organization. This is particularly true for DNPs who predominantly hold clinical positions also held by master's-prepared RNs. CONCLUSION: Advocates for continued growth of DNPs in academia and practice should partner more closely to clarify the skills and talents that doctorally-prepared nurses bring to clinical settings.
Subject(s)
Advanced Practice Nursing/statistics & numerical data , Delivery of Health Care, Integrated , Education, Nursing, Graduate , Practice Patterns, Nurses' , Professional Practice/statistics & numerical data , Female , Humans , Male , Middle Aged , Surveys and QuestionnairesSubject(s)
Indigenous Peoples/statistics & numerical data , Quality of Health Care/standards , Wound Healing , Canada , Community Health Services/methods , Community Health Services/standards , Humans , Medically Uninsured/statistics & numerical data , Quality of Health Care/statistics & numerical dataABSTRACT
BACKGROUND: HIV patients with wasting are at increased risk of opportunistic complications and fatality. OBJECTIVE: We hypothesized that augmenting dietary intake with high-biologic-value protein would enhance weight and lean tissue in weight-stable subjects with a prior unintentional weight loss of >3%. DESIGN: Fifty-nine subjects with HIV RNA concentrations <5000 copies/mL were randomly assigned to receive a 280-kcal supplement containing 40 g whey protein or a matched isocaloric control supplement without added protein twice daily for 12 wk. RESULTS: Before the study, intake of total energy and protein exceeded estimated requirements (44.3 +/- 12.6 kcal x kg(-1) x d(-1) and 1.69 +/- 0.55 g x kg(-1) x d(-1), respectively). Both supplements failed to increase total energy intake because of decreases in self-selected food intake. Changes in weight (0.8 +/- 2.4 and 0.7 +/- 2.4 kg) and lean body mass (0.3 +/- 1.4 and 0.3 +/- 1.5 kg) did not differ significantly between the whey protein and control groups, respectively. Waist-to-hip ratio improved more with whey protein (-0.02 +/- 0.05) than with the control (0.01 +/- 0.03; P = 0.025) at week 6 but not at week 12. Fasting triacylglycerol increased by 39 +/- 98 mg/dL with the control supplement and decreased by 16 +/- 62 mg/dL with whey protein at week 12 (P = 0.03). CD4 lymphocytes increased by 31 +/- 84 cells/mm(3) with whey protein and decreased by 5 +/- 124 cells/mm(3) with the control supplement at 12 wk (P = 0.03). Gastrointestinal symptoms occurred more often with whey protein. CONCLUSIONS: A whey protein supplement did not increase weight or lean body mass in HIV-positive subjects who were eating adequately, but it did increase CD4 cell counts. The control supplement with rapidly assimilable carbohydrate substituted for protein increased cardiovascular disease risk factors. Careful dietary and weight history should be obtained before starting nutritional supplements in subjects with stable weight loss and good viral control.
Subject(s)
Dietary Proteins/administration & dosage , HIV Infections/immunology , HIV Infections/metabolism , Milk Proteins/administration & dosage , Muscle, Skeletal/drug effects , Weight Loss , Adult , Aged , Body Composition/drug effects , CD4 Lymphocyte Count , Dietary Proteins/adverse effects , Dietary Supplements , Dose-Response Relationship, Drug , Double-Blind Method , Energy Intake/drug effects , Energy Intake/physiology , Female , Humans , Male , Middle Aged , Milk Proteins/adverse effects , Muscle, Skeletal/metabolism , Nutritional Requirements , Treatment Outcome , Viral Load , Weight Gain/drug effects , Weight Gain/physiology , Whey ProteinsABSTRACT
BACKGROUND: Decreased bone mineral density (BMD) is prevalent in HIV-infected patients. Bisphosphonates are currently the mainstay of treatment for postmenopausal and male osteoporosis in HIV-uninfected individuals; however, their efficacy and safety in HIV-infected patients remains unclear. METHODS: In this prospective, randomized, placebo-controlled multicenter trial, we studied the effectiveness of calcium and vitamin D supplementation with or without alendronate in improving BMD in HIV-infected subjects receiving stable antiretroviral therapy. Subjects with secondary causes of osteoporosis were excluded. The study was powered to detect differences of 3.5% between arms and to detect a moderate sex effect in percentage change in lumbar spine BMD. All dual-energy X-ray absorptiometry scans were analysed centrally, blinded by arm. RESULTS: The 82 subjects enrolled were 71% men, 77% white, with a baseline median age of 48 years, CD4 cell count of 469 cells/mul, and lumbar spine t-score of less than 2.1; 91% had HIV-RNA levels less than 400 copies/ml, and 99% were taking antiretroviral drugs. Compared with calcium/vitamin D alone, alendronate plus calcium/vitamin D resulted in significant improvements in BMD at the lumbar spine, total hip, and trochanter, but not at the femoral neck, compared with baseline. There were trends towards significant increases in BMD values in the calcium/vitamin D group at the lumbar spine, total hip, and femoral neck. There were no apparent sex differences in the responses to therapy. Alendronate was well tolerated, without significant adverse events. CONCLUSION: Once-weekly alendronate is safe and effective in the treatment of decreased BMD in HIV-infected patients.
Subject(s)
Alendronate/therapeutic use , Bone Density Conservation Agents/therapeutic use , HIV Infections/complications , Osteoporosis/drug therapy , Absorptiometry, Photon , Alendronate/adverse effects , Biomarkers/blood , Bone Density/drug effects , Bone Density Conservation Agents/adverse effects , Calcium/therapeutic use , Collagen Type I/blood , Drug Therapy, Combination , Female , Humans , Male , Osteoporosis/etiology , Osteoporosis/physiopathology , Peptides/blood , Prospective Studies , Risk Factors , Sex Factors , Treatment Outcome , Vitamin D/therapeutic useABSTRACT
Hearsay testimony from children's interviewers is increasingly common in sexual abuse trials, but little is known about its effects on juries. In 2 studies, the authors examined college students' perceptions of 3 types of hearsay testimony (an actual interview with a child or an adult interviewer providing either the gist of what that child had said or a verbatim account of the interview). Interviewers were rated as more accurate and truthful than the children. The interview was rated as higher quality, and children's statements, including their false statements, were sometimes rated as more believable in the interviewer gist hearsay condition. Mock jurors reacted differently to various types of hearsay testimony, and interviewer gist testimony may favor a child's case.